Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation
- PMID: 18489991
- DOI: 10.1016/j.bbmt.2008.03.008
Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation
Abstract
Chronic kidney disease (CKD) in recipients of myeloablative (MA) allogeneic hematopoietic cell transplantation (HCT) has been well characterized. However, the risk of CKD after HCT using reduced-intensity conditioning (RIC) is not well known. We compared the incidence of CKD by conditioning regimen in 221 allogeneic HCT recipients (MA = 117, RIC = 104) who had survived for >or=1 year post-HCT and had no history of CKD pretransplant. CKD was defined as glomerular filtration rate (GFR) <60 mL/min/1.73 m(2) for >or=3 months anytime after 180 days post-HCT. The median follow-up was 28 months (range: 12-75) for MA and 25 months (range: 12-67) for the RIC group. The 3-year cumulative incidence rate of CKD was 28% (95% confidence intervals [CI], 19%-36%) in MA and 29% (95% CI, 20%-38%) in the RIC group (P = .44). In multivariate analysis, conditioning regimen intensity had no impact on the risk of developing CKD (relative risk [RR] for MA 1.50 [95% CI, 0.78-2.89] versus the RIC regimen). Factors independently associated with an increased risk of CKD were older age at transplant, acute graft-versus-host disease, cyclosporine use for >6 months, and acute kidney injury in the early posttransplant period. CKD is frequent in long-term adult allogeneic HCT survivors, but RIC is associated with similar risks as MA conditioning. Continuous monitoring of renal function is necessary in allogeneic HCT survivors, and studies exploring prevention strategies are needed.
Similar articles
-
Early and late neurological complications after reduced-intensity conditioning allogeneic stem cell transplantation.Biol Blood Marrow Transplant. 2009 Nov;15(11):1439-46. doi: 10.1016/j.bbmt.2009.07.013. Epub 2009 Sep 1. Biol Blood Marrow Transplant. 2009. PMID: 19822304
-
Similar risks for hypothyroidism after allogeneic hematopoietic cell transplantation using TBI-based myeloablative and reduced-intensity conditioning regimens.Bone Marrow Transplant. 2009 Jun;43(12):949-51. doi: 10.1038/bmt.2008.413. Epub 2008 Dec 22. Bone Marrow Transplant. 2009. PMID: 19104492
-
Chronic kidney disease in long-term survivors of myeloablative allogeneic haematopoietic cell transplantation: prevalence and risk factors.Nephrol Dial Transplant. 2010 Jan;25(1):278-82. doi: 10.1093/ndt/gfp485. Epub 2009 Sep 17. Nephrol Dial Transplant. 2010. PMID: 19762604
-
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.Dan Med Bull. 2007 May;54(2):112-39. Dan Med Bull. 2007. PMID: 17521527 Review.
-
The evolution of hematopoietic SCT in myelodysplastic syndrome.Bone Marrow Transplant. 2009 Apr;43(8):597-609. doi: 10.1038/bmt.2009.28. Epub 2009 Mar 2. Bone Marrow Transplant. 2009. PMID: 19252532 Review.
Cited by
-
Treatment with Foscarnet after Allogeneic Hematopoietic Cell Transplant (Allo-HCT) Is Associated with Long-Term Loss of Renal Function.Biol Blood Marrow Transplant. 2020 Sep;26(9):1597-1606. doi: 10.1016/j.bbmt.2020.05.007. Epub 2020 May 23. Biol Blood Marrow Transplant. 2020. PMID: 32450288 Free PMC article.
-
Chronic kidney disease after hematopoietic stem cell transplantation.Semin Nephrol. 2010 Nov;30(6):627-34. doi: 10.1016/j.semnephrol.2010.09.010. Semin Nephrol. 2010. PMID: 21146127 Free PMC article. Review.
-
Optimal Delivery of Follow-Up Care After Allogeneic Hematopoietic Stem-Cell Transplant: Improving Patient Outcomes with a Multidisciplinary Approach.J Blood Med. 2020 May 15;11:141-162. doi: 10.2147/JBM.S206027. eCollection 2020. J Blood Med. 2020. PMID: 32523389 Free PMC article. Review.
-
Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: an update.Blood Cancer J. 2011 Apr;1(4):e16. doi: 10.1038/bcj.2011.14. Epub 2011 Apr 29. Blood Cancer J. 2011. PMID: 22829137 Free PMC article.
-
Chronic kidney disease, thrombotic microangiopathy, and hypertension following T cell-depleted hematopoietic stem cell transplantation.Biol Blood Marrow Transplant. 2010 Jul;16(7):976-84. doi: 10.1016/j.bbmt.2010.02.006. Epub 2010 Feb 12. Biol Blood Marrow Transplant. 2010. PMID: 20153836 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical